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ABSTRACT 
Objective: The development of nanomedicine, such as miRNA transfection to cancer cells, has widely gained interest in the past decade. 
Unfortunately, miRNA tends to decay easily by the cellular enzymatic process and requires a carrier. As a cationic biopolymer, chitosan is widely 
known as a non-viral vector. However, research about chitosan as a miRNA delivery system remains limited. This study aimed to investigate the 
effect and characters of synthetic miRNA loaded chitosan nanoparticles on breast cancer cell lines.  
Methods: To obtain the nanocomplex, chitosan-antimiR-106b-5p was formulated using natrium tripolyphosphate through ionic gelation methods. 
The nanochitosan formula was characterized by using gel electrophoresis; Nano Quant for encapsulation of entrapment quantification; morphology 
appearance as viewed by Scanning Electron Microscope (SEM), nanochitosan size analysis; in vitro analysis using MCF-7 and T47D breast cancer cell 
lines; in silico prediction of possible gene target; polymerase chain reaction analysis and gel electrophoresis for E2F1/GAPDH expression.  
Results: The efficiency entrapment value was 96.7 %, particle size analysis was 458±11.79 nm, and polydispersity index (PDI) was 0.65±0.07, with 
spherical morphology as viewed in SEM. There was no significant difference between the nanochitosan supplemented group and the control group 
in MCF-7 cells (p=0.067). However, the ratio of E2F1 to GAPDH was significantly lower than the control group after nanochitosan antimiR-106b-5p 
was loaded at concentration 140 nmol (p=0.022) and 35 nmol (p=0.016).  
Conclusion: Our nanochitosan formula is non-toxic to use in MCF-7 cell lines. Most importantly, as the formula was conjugated to synthetic 
antimiR-106b-5p, the E2F1 expression decreased. 
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INTRODUCTION 
miRNA therapy has gained popularity recently, with many studies 
focused on evaluating the dysregulated level of this short-chain non-
coding RNA by correlating them with altered expression of various 
genes [1]. Cancer is on the top of the priority list due to having the 
highest morbidities and mortalities reported every year [2]. In 2040, 
the World Health Organization (WHO) estimates the global burden 
of cancer will rise by approximately fifty percent from 18.1 million 
in 2018 to 27.9 million in which 2.1 million cases are caused by 
female breast cancer [3–5]. In carcinogenesis, the abnormal level of 
intracellular miRNA could affect cellular growth and proliferation, 
differentiation, apoptotic, and cell cycle to tissue development [6–8]. 
Similar to other gene therapies, miRNA expression could be 
transfected by using the synthetic oligonucleotides either as a mimic 
or antagonist [9]. Unfortunately, most gene therapies encounter 
similar challenges, especially in how to envelope the genes safely 
accompanied by their release to targeted cells precisely [10].  
To answer the challenge regarding the delivery system, scientists have 
also begun to develop various vectors to encapsulate these genes [11]. 
Nanomedicine in gene therapy applies to specific genes’ transporting 
mechanism not only in terms of size but also the packaged biochemical 
properties [12, 13]. One of the main advantages derived from drug-
based nanoparticles is its ability in enhancing the therapeutic level and 
achieving the desired pharmacological effect, especially in malignancy. 
Drug toxicity is also part of the widely discussed challenges. Achieving 
the precise dosage without affecting normal cells is partly correlated 
with the delivery system [14–16]. In cancer, nanoparticles that carry 
drugs to genes could also be designed to reach the cancer cells without 
affecting the normal cells since their size allows them to penetrate the 
cells more effectively [17–19]. To ensure its precise ability requires a 
safe, less immunogenic and biodegradable carrier. Although the viral 
vector is currently the most preferable, it still has inconvenient side 
effects such as immunogenicity, oncogenicity and the limited DNA size 
that it can uptake [20, 21]. More strategies are being developed with 
better advantages, such as cationic polymers [22]. The popularity of 
cationic biopolymers is shown by better capacity to be modified and 
ability to package certain genes. Although polyethyleneimine (PEI) has 
strong gene complexation and high transfection efficiency, studies 
reported its level of toxicity is higher than chitosan [11, 14]. 
Chitosan is a biopolymer that is widely used for medicinal purposes [23]. 
Chitosan is obtained by alkaline deacetylation of chitin, which is derived 
from crustaceans of marine arthropods or insects. The natural 
characteristic of chitosan is its positively charged surface and is 
considered perfect as a carrier for gene therapy [21]. In an acidic 
environment, chitosan can form nanoparticles and is able to interact 
with negatively charged molecules such as miRNA [24]. Several studies 
have reported chitosan as an effective nanocarrier for gene therapy. 
siRNA in PEG-chitosan nanocarriers successfully penetrated the blood-
brain barrier to reach glioblastoma cells effectively [19, 25]. Using the 
xenograft model, miR-34a encapsulated with chitosan was able to 
downregulate various metastatic genes, including MET, Axl, and c-Myc in 
prostate cancer cell lines [26]. In one study reported by Ysrafil in 2020 
also evaluated the HIF1a expression in the ovarian cancer cell line, 
SKOV3, after miR-155-5p chitosan encapsulated transfection [27]. 
However, chitosan preparation has various applicable methods. Ionic 
gelation is the most commonly used method since it is cheaper and 
only requires simple stirring. The powder base chitosan must be 
dissolved in an acidic solution and a crosslinker must be further added 
for the final formulation [10, 27]. By supplementing the chitosan 
solution with sodium tripolyphosphate, the chitosan is ready to be 
conjugated with anionic particles [28, 29]. The purposes of this study 
were to characterize and evaluate the safety of chitosan encapsulation 
for synthetic antimiR in MCF-7 cell lines then to inspect the E2F1 
mRNA expression post-transfection in a p53-mutated cell line, T47D. 
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MATERIALS AND METHODS 
Human MCF-7 and T47D breast cancer cells were obtained from ATCC 
(Virginia, USA) and maintained in high glucose Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine qualified serum 
(Massachusetts, USA), 1% Penicillin-Streptomycin (Massachusetts, USA), 
and 0.5% amphotericin (Massachusetts, USA). AntimiR-106b-5p was 
obtained from Integrated DNA Technologies (Iowa, USA). The miRCURY 
RNA Cell and Plant Kit, Universal cDNA synthesis kit II 8-64 rxns Exiqon 
was purchased from Woburn, USA. The Infinite® 200 PRO NanoQuant 
was purchased from Philadelphia, USA. Thermal Cycler (96 Well 
Capacity) PCR Select Cycler™ II was purchased from California, USA, and 
agarose gel electrophoresis system was purchased from Mupid-One® 
(Dueren, Germany). Nanoparticles Size Analyzer Sz-100 was obtained 
from Horiba Scientific (New Jersey, USA). Medium molecular weight 
chitosan was purchased from Sigma Aldrich (Missouri, USA).  
Ch-NP-antimiR-106b-5p preparation 
The chitosan-nanoparticle/antimiR was formulated by ionic gelation as 
previously demonstrated by Ysrafil et al. and Suardi et al. in 2020 [27, 
30]. It is begun by dissolving the medium molecular weight chitosan 
powder into 1% acetic acid with 24 h magnetic stirring. The solution 
later was pH adjusted to gain acid environment (pH 5.5) by adding 1 mol 
of NaOH. Then, to obtain 0.2% chitosan solution, acetate buffer pH 5 was 
added. The nanocomplex formula was later made by ionic gelation 
method by mixing 0.2% chitosan with sodium tripolyphosphate (5:1), 
then incubating for 5 min at room temperature. Next, 200 µl of the 
ready-to-use solution was conjugated with 200 µl of antimiR-106b-5p 
and incubated for 20 min at room temperature. 
Efficiency of entrapment 
Efficiency of entrapment of the chitosan encapsulated antimiR-106b-5p 
was obtained by measuring the free concentration of antimiR-106b-5p 
inside the formula. The Ch-NP-106b-5p was centrifugated for 15 min at 
13000 g speed. The supernatant obtained was measured by its 
absorbance using The Infinite® 200 PRO NanoQuant. Then, the 
absorbance efficiency was formulated as follows by comparing the 
percentage of encapsulated miRNA to total miRNA [27, 31]. 
Total miRNA − unencapsulated miRNA
total miRNA
×  100% 
Ch-NP-antimiR-106b-5p morphology measurement 
Chitosan antimiR-106b-5p nanocomplex was prepared as 3 µmol 
concentrate by diluting it into nuclease-free water as mentioned and 
referred to from Suardi et al. in 2020 [30]. To measure the size, a 
Nanoparticle Size Analyzer Horiba Sz-100 was used and to evaluate 
the morphology, Scanning Electron Microscope (SEM) was used. 
Cell viability assay 
We observed and analyzed the cells’ tolerability toward the chitosan 
solution by using cytotoxic tests on MTT assay method [32]. T47D 
and MCF-7 cells were seeded into 96 well plates with approximately 
6x103 cells in each well plate, then incubated for 24 h at 37 °C and 
5% CO2. The next day, the media was removed from each well and 
the cells were given 100 µl of nanochitosan solution or high glucose 
DMEM only as the control group. MTT assay was then conducted 
after 24 h of incubation by pipetting 100 µl of 0.5 mg/ml MTT 
reagent in each well. After incubating the solution for 4 h, then 100 
µl stopper solution (SDS 10% and 0.01 µl/l HCl) was added to 
dissolve the formazan crystals. The solution was then incubated 
again for the next 18 h in room temperature with the absence of 
light. The absorbance of each well was measured at a 595 nm 
wavelength using Micro Plate Reader (Bio-Rad Model 680 XR). 
Genes target expression analysis 
T47D cells were seeded about 5x104 each well into a 6 well plate. 
Following 24 h of incubation, nanochitosan encapsulated antimiR-
106b-5p was then added to each well with three different 
concentrations and incubated again for the next 24 h [27]. Total RNA 
was isolated using miRCURY RNA Cell and Plant Kit according to the 
manufacturer’s protocol. Total RNA concentrations were measured 
by NanoQuant at 260 to 280 nm wavelengths. To gain the reverse 
transcribed RNA, 10 ng of total RNA was synthesized by using 
Universal cDNA synthesis kit II 8-64 rxns according to the 
manufacturer’s protocol. Quantification of E2F1 mRNA used the 
following primers: (forward: ACTCCTCGCAGATCGTCATCATCT; 
reverse: GGACGTTGGTGATGTCATAGAT), and GAPDH as 
housekeeping gene (forward: GGCAAATTCAACGGCACAGT; reverse: 
AGATGGTGATGGGCTTCCC). The polymerase chain reaction (PCR) 
products were later run through 2% agarose gel electrophoresis. 
The bands were quantified using ImageJ software. 
Statistical analysis 
All the analyzed data were measured in triplicate and outcome 
values were presented as mean±standard deviation (SD). We 
compared the cells viability between the chitosan nanoparticles (Ch-
NP) with miRNA loaded as the experiment group with the high 
glucose DMEM as the control group using Independent T-tests. Gene 
target expressions were analyzed with Independent T-tests. All 
presented data were analyzed using SPSS 25 software (SPSS Inc., 
Chicago, USA) and graphics were performed by GraphPad Prism 8.0. 
Statistical significance was set at p<0.05. 
RESULTS AND DISCUSSION 
Efficiency of entrapment 
To evaluate the presenting synthetic oligonucleotides encapsulated 
by the nanochitosan formula, we labeled both the naked and Ch-NP-
antimiR-106b-5p with fluorochrome and ran it through 2% agarose 
gel electrophoresis for 15 min. As viewed from the GelDoc, the well 
from the naked antimiR showed in the background as a greyish 
white area between the dark backgrounds while the encapsulated 







Fig. 1: (A) Agarose gel electrophoresis of chitosan/antimiRNA (1) Naked antimiR (2); (B) Efficiency of entrapment of the Ch-NP-antimiR-
106b-5p as measured by NanoQuant and spherical morphology of nanochitosan was visualized by Scanning Electron Microscope, 
Abbreviation: Ch-NP-antimiR-106b-5p: Chitosan Nanoparticle antimiRNA-106b-5p 
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We also quantified the efficiency of entrapment using NanoQuant to 
measure the percentage of total miRNA encapsulated by the 
nanochitosan. Using the formula, the value of the efficiency of 
entrapment was 96.7% (fig. 1B). The obtained value indicated the total 
miRNA concentrations encapsulated by the chitosan nanocomplex 
through ionic gelation with sodium tripolyphosphate. The spherical 
morphology of the nanochitosan also has a meaningful contribution as 
viewed from SEM analysis, making it easily distinguishable (fig. 1B). 
Morphology analysis of Ch-NP-antimiR-106b-5p 
We conducted particle size analysis of the encapsulated antimiR-
106b-5p to evaluate the nanocomplex formation by the chitosan. We 
obtained the size of nanoparticles 458±11.79 nm with 
Polydispersity Index (PDI) 0.65±0.07 (table 1). With PDI less than 
0.7, the nanoparticles would likely distribute uniformly and this 
would strengthen their ability to reach the intracellular [33]. 
  
Table 1: Nanochitosan distribution and size analysis (n=3) 
 Particle size Polydispersity Index (PDI) 
Ch-NP-antimiR-106b-5p 458±11.79 nm 0.65±0.07 
Abbreviation: Ch-NP-antimiR-106b-5p: Chitosan Nanoparticle antimiRNA-106b-5p. (n=3) and data were given in mean±SD. 
 
Cell viability after nanochitosan transfection 
We performed the simplest and most effective calorimetric assay (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(methyl thiazolyl tetrazolium; MTT)) to identify the mitochondrial 
activity of cytochrome b and c from surviving cells. The living cells 
were shown as purple rings (formazan crystals). This assay was 
performed on all groups (chitosan supplemented cells and high 
glucose DMEM only). The absorbance values obtained later were 
analyzed and compared to the control group. We conducted an 
Independent T-tests test since our data were normally distributed. As 
observed by the absorbance values, there was no significant difference 
neither in the nanochitosan nor in the control group (p=0.067).  
In silico identification of miRNA target prediction  
Furthermore, we also conducted the bioinformatic analysis to 
predict the binding location of E2F1 mRNA toward the miR-106b-
5p. As predicted by the tools, miR-106b-5p could recognize EF21 at 
base number 1972-1987 from the chromosome locus with logistic 
probability of 0.74. The near 1 value of logistic probability marked 
the highest confidence of the binding location. 
 
Fig. 2: MCF-7 cells, after given the chitosan nanoparticles, 
showed no significant cell diminishing (n=3). Data were 
presented as mean±SD with *p<0.05 versus the control group 
(untreated cell line) 
 
 
Fig. 3: In silico approach of miR-106b-5p-E2F1 recognition and binding prediction using STarMirDB combined with GeneCard 
 
E2F1 mRNA expression analysis after Ch-NP-antimiR-106b-5p 
transfection to T47D cells 
We measured the gene target expression by running the extracted 
RNA through PCR to predict the nanoparticles’ ability to deliver the 
synthetic oligonucleotides intracellular into its functional location 
on T47D cells. The cells were seeded and incubated into 6 well plate 
for 24 h continued with antimiR-chitosan transfection for the next 
24 h. The cDNA from each concentration group (140 nmol, 70 nmol, 
35 nmol and control group) were diluted and mixed with the PCR 
MasterMix reagents (GoTaqGreen) then run through 2% gel agarose 
electrophoresis. As seen in fig. 4, E2F1/housekeeping gene GAPDH 
mRNA expression was significantly lower in all dosages given 
compared to the control group treated with free serum DMEM only 
(Independent T-test; p<0.05) in two different concentrations: 140 
nmol and 35 nmol. 
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A     B 
Fig. 4: (A) Electrophoresis band of endogenous E2F1/GAPDH mRNA level after Ch-NP-antimiR-106b-5p transfection given in three 
different concentrations: 35 nmol, 70 nmol and 140 nmol compared to control group. (B) endogenous E2F1/GAPDH mRNA level 
quantified by RT-PCR, from left to right at concentrations: (a) 35 nmol, (b) 70 nmol, (c) 140 nmol and (d) control group; (n=3). Data were 
presented as mean±standard deviation (SD) with *p<0.05 versus control group (untreated cell line) 
Abbreviation: E2F1, E2F Transcription Factor 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RT-PCR, reverse transcription-
polymerase chain reaction 
 
Targeted therapy has become more desirable in the last few decades 
due to its great potential in solving numerous challenges that have 
occurred in efforts to eradicate certain diseases, especially cancer. 
The studies of miRNA have gained popularity since it belongs to 
non-coding RNA, which are able to interact with abundant target 
genes involved in tumorigenesis. It also could affect changes at the 
functional protein level [31]. Unfortunately, it is almost impossible 
to transfect the miRNA into the intracellular and penetrate the 
membranes safely. The dehydrogenase enzymes can decay it even 
before reaching the surface so it may lose efficiency due to its 
inability to conjugate with certain ligands. In terms of predicting the 
solution, many vectors have been developed to solve this problem 
and using biopolymers is another strategy to replace the highly 
immunogenic plasmid viral vector [14]. 
As an effective drug deliverer, the popularity of chitosan is well-
known due to its ability to penetrate into the tight junction of cell 
membranes effectively, with low immunogenicity and 
biodegradability, while its polycationic character by nature makes it 
easy to interact with negative charged nucleic acids [15, 34]. To 
formulate the chitosan requires certain methods and ionic gelation 
simple complexation is the easiest technique. It is made by 
conjugating the chitosan with anionic multivalent tripolyphosphate 
(TPP) as the crosslinker. The TPP will create strong binding flex with 
the amine molecules of chitosan to stabilize the matrix. In addition, 
TPP is less toxic compared to any other chemical crosslinker, such as 
glutaraldehyde [28, 35, 36]. In this study, we aimed to formulate the 
nanochitosan by using the medium molecular weight chitosan under 
an acidic environment. Molecular weight may affect the transfection 
ability and medium weight has notable advantages to induce better 
bioavailability since it carries more amines and hydroxyl molecules 
inside. The acidity of the dissolving solution also enhances the 
protonation among the amine molecules [36, 37]. 
A few studies suggested the optimal ratio of chitosan: TPP is about 6:1 
(Morris et al., 2011). Also, another study revealed the effective ratio 
for chitosan-PEG5k: TPP: miRNA is 30:4:1 and optimized by 
fluorescence observation with DyS47 labelled miR-67 mimic. From 
this ratio, the obtained efficiency of encapsulation is 60 % [31]. 
However, as mentioned in one study by Al-Nemrawi et al. in 2018, the 
nanoparticles tend to form bigger sizes when the TPP was added up to 
3 mg into the solution [38]. The change of ratio between the chitosan 
and TPP could also alter the particle size and PDI. It is expected to 
increase the particle growth after increasing the ratio from 25:5 to 
25:10 as mentioned in a study by Hassan et al. in 2018 [39]. In this 
study, we used the nanochitosan formula optimized by Ysrafil et al. in 
2020 with 5:1 ratio of chitosan: TPP. The optimization ratio was tested 
on SKOV3 cells using cellular uptake measurement by labelling the 
miRNA with FAM-conjugated label [27].  
Furthermore, chitosan nanoparticle exact size could be affected by 
chitosan concentration. To obtain less than 500 nm nanoparticle 
size, Katas et al. in 2013 reduced the concentration to about 0.05% 
[40]. Higher concentration (>0.25 %) may induce spontaneous 
coacervation of the formed particles as 1000 nm particles. To avoid 
the possibility of a bigger size, we used the optimized 0.2% chitosan 
concentration according to Ysrafil’s study in 2020 [27]. However, the 
chitosan size particle also depends on the amount of TPP added in 
the ionic gelation methods [41]. We found the formula we referred 
from Ysrafil et al. in 2020 still showed the result was less than 500 
nm nanoparticle size and was exactly 458 nm.  
Nanochitosan transfection optimization has also been shown by 
antimiR-fluorochrome labelling. The subtle illuminance on naked 
antimiR implied some of the oligonucleotides retracted under the 
positive charge given from the electrophoresis. Meanwhile, the 
encapsulated antimiR stayed at the well base, which indicated the 
predicted oligonucleotides entrapment by chitosan. The capsulation 
under polycationic chitosan engages the nucleic acids to form more 
positive charged particles. As the response, the electrostatic energy 
from the agarose gel failed to pull the nanocomplex downward. To 
analyze the predicted entrapment efficiency, we used the formula to 
measure the unencapsulated miRNA with NanoQuant. We obtained 
96.7% of encapsulation efficiency from the nanocomplex formula. 
This high percentage may correlate with nearly completely 
condensate oligonucleotides by the nanochitosan matrix. 
Results from the 24 h of incubation of MCF-7 cells after given 200 µl 
of the nanochitosan formula showed no significant cells diminishing 
compared to high glucose DMEM supplemented cells as the control 
group (fig. 2). This result implied that the cell viability remained 
normal and could grow. Compared to NaCl, unmodified chitosan has 
a lower toxicity value (LD50: 16 g/kg, while LD50 for NaCl is 3 g/kg) 
[14]. As reported by Kean and Thanou in 2010, median lethal dose 
(LD50) and half-maximal inhibitory (IC50) for chitosan and its 
derivates in all cells model are approximately 0.2-2.5 mg/ml [42], 
which is much lower compared to any other biopolymer or liposome 
based vector.  
We also assessed the effect of antimiR chitosan encapsulation 
transfection on T47D cells after overnight incubation. Stender et al. 
in 2007 reported by using biochemical and bioinformatics analysis 
to MCF-7 and MDA-MB-231 cells, E2F1 gene is associated with E2 
activity during tumor progression [43]. However, since p21 gene as 
the negative control is mostly suppressed by miR-106b-5p activity, 
the oncogene CIP2A could inhibit the phosphatase of phosphatase-
tumor suppressor complex, PP21, and induces the E2F1 
overexpression [44]. As shown in fig. 4, with the E2F1 relative 
expression toward the GAPDH as a stabile housekeeping gene, the 
significant value was only marked on two different antimiR 
concentrations, at the lowest and highest concentration, compared 
to the control group. Our in silico assessment showed the E2F1 is 
one of the strong gene targets of miR-106b-5p. E2F1 is a 
transcription factor for numerous genes involved for DNA 
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replications [45]. During the cell cycle, cyclin-dependent kinase 
(CDK) phosphorylated the tumor suppressor protein retinoblastoma 
protein (pRB) and released E2F1 for various genes, which could be 
expressed during DNA synthesis, including mitosis [46]. Some 
studies also suggested the transcription of miR-106b-25 involved 
E2F1 activity [47]. T47D cells as part of the luminal A type cell line 
along with MCF-7 expressed abundant ERα in the cytosolic 
membranes and the receptors as suggested by Louie et al. in 2010, 
while E2F1 as a cell cycle transcription gene could be modulated by 
the ERα together with Sp-1 protein [48]. These findings indicate the 
plausible reasons for why our E2F1 level only decreased slightly.  
CONCLUSION 
In summary, we concluded that chitosan nanoparticle could be used 
as an effective transfecting courier for nucleic acid such as 
microRNA into the cells without showing toxicity toward the cells. 
Furthermore, in vitro study revealed that antimiR-106b-5p 
conjugated with chitosan nanoparticle could induce the expression 
of E2F1 mRNA after transfection. 
To verify the strong correlation after treatment, endogenous miR-
106b-5p expression should be measured and the values plotted with 
the mRNA target. Fluorescence-labelled synthetic oligonucleotides 
(FITC) is also another alternative to evaluate the miRNA-loaded 
nanochitosan uptake into cells. 
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